Abstract
32D cells expressing v-Ha-Ras fail to show a transformed phenotype. Since Ras requires an active IGF-1R for transformation of fibroblasts, we asked whether expression of IRS-1 or Shc (two of the major substrates of the IGF-1R) could co-operate with oncogenic Ras in transforming 32D cells. We find that IRS-1, but not Shc, in combination with v-Ha-Ras generates a fully transformed phenotype in 32D cells. 32D cells expressing both IRS-1 and v-Ha-Ras (32D/IRS1/Ras) survive and proliferate in the absence of IL-3, do not undergo granulocytic differentiation in the presence of G-CSF and form tumors in nu/nu and syngeneic mice. In contrast, 32D cells expressing singly IRS-1 or v-Ha-Ras exhibit only a block in differentiation capacity. Over-expression of Shc proteins, by itself, promotes differentiation of 32D cells. Concomitant expression of IRS-1 and v-Ha-Ras synergistically phosphorylates ERK-1 and ERK-2 whereas a MEK inhibitor rapidly induces death of 32D/IRS1/Ras transformed cells. Furthermore, transformed 32D/IRS1/Ras cells display high levels of PI3-K activation and undergo rapid apoptosis when exposed to PI3-K inhibitors. The data indicate that: (1) a fully transformed phenotype in 32D cells is generated when a block in differentiation (v-Ha-Ras) is coupled with another differentiation block (IRS-1); (2) PI3-K and MAPK activity are required for the survival of transformed cells; (3) the signals generated by IRS-1 and oncogenic Ras converge on ERK and PI3-K resulting in high levels of activation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Araki E, Sun XJ, Haag BL, Chuang LM, Zhang Y, Yang-Feng TL, White MF and Kahn CR. . 1993 Diabetes 42: 1041–1054.
Askew DS, Ashmun RA, Simmons BC and Cleveland JL. . 1991 Oncogene 6: 1915–1922.
Avruch J. . 1998 182: 31–48.
Baserga R, Hongo A, Rubini M, Prisco M and Valentinis B. . 1997 Biochim. Biophys. Acta 1332: (3) 105–126.
Bos JL. . 1989 Cancer Res. 49: 4682–4689.
Chaturvedi P, Sharma S and Reddy P. . 1997 Mol. Cell. Biol. 17: 3295–3304.
Cheng J and Haas M. . 1990 Mol. Cell. Biol. 10: 5502–5509.
D'Ambrosio C, Keller SR, Morrione A, Lienhard GE, Baserga R and Surmacz E. . 1995 Cell Growth & Differ. 6: 557–562.
Dews M, Prisco M, Peruzzi F, Romano G, Morrione A and Baserga R. . 2000 Endocrinology 141: in press.
Dews M, Nishimoto I and Baserga R. . 1998 Recept. Signal Transduc. 7: 231–240.
Engelman JA, Lisanti MP and Scherer PE. . 1998 J. Biol. Chem. 273: 32111–32120.
Greenberger JS, Eckner RJ, Sakakeeny A, Marks P, Reid D, Nabel G, Hapel A, Ihle JN and Humphries KC. . 1983 Fed. Proc. 42: 2762–2771.
Groopman JE, Molina JM and Scadden DT. . 1989 N. Engl. J. Med. 321: 1449–1459.
Hugl SR, White M and Rhodes CJ. . 1998 J. Biol. Chem. 273: 17771–17779.
Kastan MB, Radin AI, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, Stone KD, Woo T, Ravindranath Y and Craid RW. . 1991 Cancer Res. 51: 4279–2286.
Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH and Downward J. . 1997 EMBO J. 16: 2783–2793.
Kulik G, Klippel A and Weber MJ. . 1997 Mol. Cell. Biol. 17: 1595–1606.
Kulik G and Weber MJ. . 1998 Mol. Cell. Biol. 18: 6711–6718.
Lanfrancone L, Pelicci G, Brizzi MF, Aronica MG, Casciari C, Giuli S, Pegoraro L, Pawson T and Pelicci PG. . 1995 Oncogene 10: 907–917.
Mavilio F, Kreider BL, Valtieri M, Naso G, Shirsat N, Venturelli D, Reddy EP and Rovera G. . 1989 Oncogene 4: 301–308.
Metcalf D. . 1985 Blood 65: 357–362.
Myers MG, Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J and White MF. . 1994 J. Biol. Chem. 269: 28783–28789.
Myers MG, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM and White MF. . 1993 Endocrinology 132: 1421–1430.
Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B and Baserga R. . 1999 Mol. Cell. Biol. 19: 7203–7215.
Peterson JE, Kulik G, Jelinek T, Reuter CW, Shannon JA and Weber MJ. . 1996 J. Biol. Chem. 271: 31562–31571.
Prisco M, Hongo A, Rizzo MG, Sacchi A and Baserga R. . 1997 Mol. Cell. Biol. 17: 1084–1092.
Sawyers CL, Denny CT and White ON. . 1991 Cell 64: 337–350.
Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M and Sacchi A. . 1996a J. Cell. Biol. 134: 193–204.
Soddu S, Blandino G, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M and Sacchi A. . 1996b Mol. Cell. Biol. 16: 487–495.
Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH and Li W. . 1999 Mol. Cell. Biol. 19: 3816–3828.
Tanaka S, Ito T and Wands JR. . 1996 J. Biol. Chem. 271: 14610–14616.
Valentinis B, Morrione A, Peruzzi F, Prisco M, Reiss K and Baserga R. . 1999a Oncogene 18: 1827–1836.
Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, Soddu S, Cristofanelli B, Sacchi A and Baserga R. . 1999b J. Biol. Chem. 274: 12423–12430.
Valtieri M, Tweardy DJ, Caracciolo D, Johnson K, Mavilio F, Altmann S, Santoli D and Rovera G. . 1987 J. Immunol. 138: 3829–3835.
Wang LM, Myers MG, Sun XJ, Aaronson SA, White M and Pierce JH. . 1993 Science 261: 1591–1594.
White MF. . 1998 Mol. Cell. Biochem. 182: 3–11.
Yenush L, Fernandez R, Myers TC, Grammer MG, Sun XJ, Blenis J, Pierce JH, Schlessinger J and White MF. . 1996 Mol. Cell. Biol. 16: 2509–2517.
Zhou-Li F, Xu SQ, Dews M and Baserga R. . 1997 Oncogene 15: 961–970.
Acknowledgements
This work was partially supported by Finalized Projects of AIRC, Italy-USA, Ministero della Sanità and by grants PO1 CA 56309 and CA 53424 from the National Institutes of Health (R Baserga). G Bossi is recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cristofanelli, B., Valentinis, B., Soddu, S. et al. Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. Oncogene 19, 3245–3255 (2000). https://doi.org/10.1038/sj.onc.1203664
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203664
Keywords
This article is cited by
-
Expression and function of the insulin receptor substrate proteins in cancer
Cell Communication and Signaling (2009)
-
Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes
Oncogene (2008)
-
Insulin Receptor Substrates (IRSs) and Breast Tumorigenesis
Journal of Mammary Gland Biology and Neoplasia (2008)
-
Recruitment of insulin receptor substrate-1 and activation of NF-κB essential for midkine growth signaling through anaplastic lymphoma kinase
Oncogene (2007)
-
Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors
Leukemia (2006)